Newly-Issued Broad Composition of Matter Patent Protects VistaGen Therapeutics, Inc.’s ES-Cell Derived Pluripotent Precursor Cells

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc., a biotechnology company using leading-edge embryonic stem cell (ES Cell) technologies for predictive toxicology and drug discovery, has announced new broad composition of matter patent protection for its ES Cell-derived pluripotent precursor cells. VistaGen has exclusive rights for commercial use in its ES Cell-based tools platform for drug discovery and development.